NANP and malaria: One review of nine trials of vaccines targeted at the sporozoite or liver stages (CS-NANP, CS102, ME-TRAP and RTS, S) found that only (RTS, S) reduced clinical episodes of malaria by 26% (95% CI 13% to 37%) in semi-immune children for up to 18 months [54].